IPILIMUMAB IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN AS FIRST-LINE TREATMENT IN EXTENSIVE DISEASE-SMALL CELL LUNG CANCER (ED-SCLC): RESULTS FROM A PHASE 2 TRIAL

被引：0
|
作者：
Reck, Martin [1 ]
Bondarenko, Igor [2 ]
Luft, Alexander [3 ]
Serwatowski, Piotr
Barlesi, Fabrice [4 ]
Chacko, Raju [5 ]
Sebastian, Martin [6 ]
Siegel, Jonathan [7 ]
Cuillerot, Jean-Marie [7 ]
Lynch, Thomas [8 ,9 ]
机构：
[1] Hosp Grosshansdorf, Dept Thorac Oncol, Grosshansdorf, Germany
[2] City Clin Hosp, Kiev, Ukraine
[3] Leningrad Reg Clin Hosp, St Petersburg, Russia
[4] Univ Aix Marseille 2, Assistance Publ Hop Marseille, Marseille, France
[5] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India
[6] Johannes Gutenberg Univ Med Ctr, Dept Hematol Oncol & Pneumol, Mainz, Germany
[7] Bristol Myers Squibb Co, New York, NY 10154 USA
[8] Yale Canc Ctr, Dept Oncol, New Haven, CT USA
[9] Smilow Canc Hosp, New Haven, CT USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：S310 / S311
页数：2
相关论文
共 50 条
  • [41] Cisplatin - Paclitaxel - Topotecan (CPT) weekly administration in chemo-naive or pretreated extensive disease small cell lung cancer (ED-SCLC). A SICOG Phase II study
    Panza, N
    Frasci, G
    Comella, P
    Nicolella, G
    Natale, M
    Muci, D
    Palmeri, S
    Ruffolo, P
    Gravina, A
    Comella, G
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S252 - S252
  • [42] Randomized phase II study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin versus etoposidecisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC)
    O'Brien, M.
    Jassem, J.
    Lorigan, P.
    Bosquee, L.
    Marshall, E.
    Bustin, F.
    Stigt, J.
    Dingemans, A. C.
    Hasan, B.
    Van Meerbeeck, J. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [43] RESULTS OF A RANDOMIZED PHASE III STUDY OF SINGLE-AGENT AMRUBICIN (AMR) VERSUS CARBOPLATIN AND ETOPOSIDE (CE) IN ELDERLY PATIENTS WITH EXTENSIVE-DISEASE SMALL CELL LUNG CANCER (ED-SCLC)
    Hida, N.
    Okamoto, H.
    Horai, T.
    Nakagawa, K.
    Nishiwaki, Y.
    Yokoyama, A.
    Katakami, N.
    Shibuya, M.
    Saijo, N.
    Fukuoka, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 148 - 148
  • [44] Updated Results of Camrelizumab Plus Nab-Paclitaxel and Carboplatin as First-Line Treatment for ES-SCLC: A Phase II Trial
    Ren, S.
    Yu, J.
    Xiong, A.
    Wang, Q.
    Wang, L.
    Chen, B.
    Yang, M.
    Li, W.
    Yuan, J.
    Zhao, C.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S373 - S374
  • [45] Prognostic Factors in Extensive Disease (ED) Small Cell Lung Cancer (SCLC): An ELCWP Phase III Randomized Trial
    Berghmans, Thierry
    Lafitte, Jean -Jacques
    Meert, Anne -Pascale
    Scherpereel, Arnaud
    Paesmans, Marianne
    Leclercq, Nathalie
    Sculier, Jean-Paul
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S721 - S721
  • [46] Anlotinib Plus Etoposide and Carboplatin as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer: A Single Arm Phase II Trial
    Han, B.
    Zhang, W.
    Zhang, B.
    Chen, Y.
    Zhang, Y.
    Lou, Y.
    Dong, Y.
    Qian, F.
    Zhou, W.
    Yang, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S503 - S503
  • [47] Phase III study comparing cyclophosphamide, doxorubicin, and etoposide (CDE) to carboplatin and paclitaxel (CP) in patients (pts) with extensive disease small cell lung cancer (ED SCLC).
    Smit, EF
    Groen, HJM
    Biesma, B
    van der Wilt, S
    Koolen, MGJ
    De Jong, WK
    Tinteren, HV
    Bochove, AV
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 631S - 631S
  • [48] Randomized phase 2 study of efatutazone in combination with carboplatin and paclitaxel as first-line therapy for metastatic non-small cell lung cancer (NSCLC)
    Shaw, Alice T.
    Ghizdavescu, Doru
    Jain, Minish
    Volovat, Constantin
    Subramaniam, Deepa
    Shuster, Dale
    Jin, Xiaoping
    Dutta, Dipen
    Pai, Seema
    von Roemeling, Reinhard
    CANCER RESEARCH, 2012, 72
  • [49] A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
    Paz-Ares, Luis
    Balint, Beatrix
    de Boer, Richard H.
    van Meerbeeck, Jan P.
    Wierzbicki, Rafal
    De Souza, Paul
    Galimi, Francesco
    Haddad, Vincent
    Sabin, Tony
    Hei, Yong-jiang
    Pan, Yang
    Cottrell, Susan
    Hsu, Cheng-Pang
    RamLau, Rodryg
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (03) : 329 - 337
  • [50] Carboplatin plus Weekly Paclitaxel with Bevacizumab for First-line Treatment of Non-small Cell Lung Cancer
    Kubota, Tetsuya
    Okano, Yoshio
    Sakai, Mizu
    Takaoka, Masato
    Tsukuda, Tsukie
    Anabuki, Kazuki
    Kawase, Shigeo
    Miyamoto, Shintaro
    Ohnishi, Hiroshi
    Hatakeyama, Nobuo
    Machida, Hisanori
    Urata, Tomoyuki
    Yamamoto, Akira
    Ogushi, Fumitaka
    Yokoyama, Akihito
    ANTICANCER RESEARCH, 2016, 36 (01) : 307 - 312
12345